Advantages
As new markers continue to be discovered in an effort to redefine the drug development process, the AVANTRA ® biomarker workstation will be a valuable tool to enable validation of biomarkers in preclinical trials as well as provide a direct transition into clinical trials.
Clinical Trials Testing
AVANTRA ® Biomarker Workstation
Avantra Bioscience technology provides precision multiplex assays, enabling evaluation of biomarker panels with a high level of accuracy. The AVANTRA ® biomarker workstation is the only commercially available fully automated multiplex immunoassay system for proteins that can transition directly from preclinical to clinical trials testing, using the same platform while providing the same levels of performance. This will translate to more effective clinical trials and earlier, more cost effective decision making.
A Breakthrough in Technology
Research at Avantra Bioscience has led to technology breakthroughs in microarray surface chemistry, immunoassay automation and detection optics. Our proprietary technologies include an enabling surface coating for protein binding, a unique reagent delivery system for ELISA automation and a novel microarray imaging system
What We Offer
We have combined our expertise and technology innovations to develop the AVANTRA ® Biomarker Workstation , the first multiplex immunoassay system to deliver high-precision results for biomarker panels. Our system offers unmatched sensitivity, accuracy, ease-of-use, assay dynamic range, and low capital cost.
Our Goal
Multiplex protein biomarker analysis is becoming increasingly important as a tool in the drug development process as scientists continue to understand the complex nature of diseases. In developing our technologies and creating the AVANTRATQ400 biomarker workstation, our goal is to address the unmet needs currently impacting the development lifecycle within the pharmaceutical and biotech industries; namely, increased requirements for data accuracy and precision, particularly as biomarker screening begins to transition to validation and clinical deployment.